Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-08T10:30:57.080Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics

Published online by Cambridge University Press:  15 April 2020

S. Heres ,
M. Lambert  and
R. Vauth
S. Heres*
Affiliation:
Klinik und Poliklinik für Psychiatrie und Psychotherapie der Technischen Universität München, Ismaningerstraße 22 München81675Germany
M. Lambert
Affiliation:
Psychosis Centre, Department of Psychiatry and Psychotherapy Centre of Psychosocial Medicine University Medical Centre Hamburg-Eppendorf Martinistraße 52 Hamburg20251Germany
R. Vauth
Affiliation:
Psychiatric University Clinics University of Basel, Centre for Mental Health Kornhausgasse 7 Basel4051Switzerland
*
*Corresponding author: Klinik und Poliklinik für Psychiatrie und Psychotherapie der Technischen Universität München, Ismaningerstraße 22, 81675 München, Germany. Tel.: + 49 89 4140 4227; fax: + 49 89 4140 7339.[email protected]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The use of long-acting injectable antipsychotics (LAIs) in schizophrenia is usually restricted to patients in long-term treatment, who prefer them to oral antipsychotics, and to patients with multiple relapses who have a history of non-adherence. However, preliminary evidence from patients in the early phases of the disease suggest that second generation LAIs may be superior to second generation oral medications with regard to the control of negative symptoms and psychosocial functioning. Moreover, several studies have found that psychiatrists are generally reluctant to prescribe LAI antipsychotics and under-estimate their acceptability by patients. Key elements to take into account when offering a LAI in the early course of schizophrenia should include their potential superiority in allowing early detection of non-adherence and in reducing the number of rehospitalisations and relapses.

Keywords

SchizophreniaAntipsychoticLong-acting injectionsFirst episodeRecent onset
Type
Review
Information
European Psychiatry , Volume 29 , Issue S2: Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics , November 2014 , pp. 1409 - 1413
Copyright
Copyright © European Psychiatric Association 2014

References

Robinson, D, Woerner, MG, Alvir, JM, Bilder, R, Goldman, R, Geisler, S , et al.Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56 1999 241247CrossRefGoogle ScholarPubMed
Chien, WT, Yip, ALCurrent approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments. Neuropsychiatr Dis Treat 9 2013 13111332CrossRefGoogle ScholarPubMed
Leucht, S, Zhao, JEarly improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program. J Psychopharmacol 28 2014 387394CrossRefGoogle ScholarPubMed
Johnson, DAObservations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry 45 1984 1321Google ScholarPubMed
Davis, JM, Matalon, L, Watanabe, MD, Blake, L, Metalon, LDepot antipsychotic drugs. Place in therapy. Drugs 47 1994 741773CrossRefGoogle ScholarPubMed
Barnes, TR, Curson, DALong-term depot antipsychotics. A risk-benefit assessment. Drug Saf 10 1994 464479CrossRefGoogle ScholarPubMed
Stahl, SMLong-acting injectable antipsychotics: shall the last be first? CNS Spectr 19 2014 35CrossRefGoogle ScholarPubMed
Emsley, R, Chiliza, B, Asmal, L, Mashile, M, Fusar-Poli, PLong-acting injectable antipsychotics in early psychosis: a literature review. Early Interv Psychiatry 7 2013 247254CrossRefGoogle ScholarPubMed
Taylor, M, Ng, KYShould long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review. Aust N Z J Psychiatry 47 2013 624630CrossRefGoogle ScholarPubMed
Altamura, AC, Aguglia, E, Bassi, M, Bogetto, F, Cappellari, L, De Giorgi, S , et al.Rethinking the role of long-acting atypical antipsychotics in the community setting. Int Clin Psychopharmacol 27 2012 336349Google ScholarPubMed
Jaeger, M, Rossler, WAttitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res 175 2010 5862CrossRefGoogle ScholarPubMed
Heres, S, Reichhart, T, Hamann, J, Mendel, R, Leucht, S, Kissling, WPsychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophrenia. Eur Psychiatry 26 2011 297301CrossRefGoogle ScholarPubMed
Tiihonen, J, Haukka, J, Taylor, M, Haddad, PM, Patel, MX, Korhonen, PA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168 2011 603609CrossRefGoogle Scholar
Birchwood, M, Todd, P, Jackson, CEarly intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl 172 1998 5359CrossRefGoogle ScholarPubMed
Cassidy, CM, Norman, R, Manchanda, R, Schmitz, N, Malla, ATesting definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years. Schizophr Bull 36 2010 10011008CrossRefGoogle ScholarPubMed
Jaaskelainen, E, Juola, P, Hirvonen, N, McGrath, JJ, Saha, S, Isohanni, M , et al.A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 39 2013 12961306CrossRefGoogle Scholar
Emsley, R, Oosthuizen, PP, Koen, L, Niehaus, DJ, Martinez, GSymptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J Clin Psychiatry 73 2012 e541e547CrossRefGoogle ScholarPubMed
Leucht, S, Tardy, M, Komossa, K, Heres, S, Kissling, W, Davis, JMMaintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 5 2012 CD008016.Google Scholar
Lieberman, JA, Alvir, JM, Koreen, A, Geisler, S, Chakos, M, Sheitman, B , et al.Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 14 1996 13S21SCrossRefGoogle Scholar
Wiersma, D, Nienhuis, FJ, Slooff, CJ, Giel, RNatural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull 24 1998 7585CrossRefGoogle ScholarPubMed
Lieberman, JA, Perkins, D, Belger, A, Chakos, M, Jarskog, F, Boteva, K , et al.The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 50 2001 884897CrossRefGoogle ScholarPubMed
Takeuchi, H, Suzuki, T, Uchida, H, Watanabe, K, Mimura, MAntipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res 134 2012 219225CrossRefGoogle ScholarPubMed
Zipursky, RB, Menezes, NM, Streiner, DLRisk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res 152 2014 408414CrossRefGoogle ScholarPubMed
Gitlin, M, Nuechterlein, K, Subotnik, KL, Ventura, J, Mintz, J, Fogelson, DL , et al.Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 158 2001 18351842CrossRefGoogle ScholarPubMed
Chen, EY, Hui, CL, Lam, MM, Chiu, CP, Law, CW, Chung, DW , et al.Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ 341 2010 c4024CrossRefGoogle ScholarPubMed
Kane, JMTreatment strategies to prevent relapse and encourage remission. J Clin Psychiatry 68 Suppl 14 2007 2730Google ScholarPubMed
Thornicroft, G, Brohan, E, Rose, D, Sartorius, N, Leese, MGlobal pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey. Lancet 373 2009 408415CrossRefGoogle ScholarPubMed
Almond, S, Knapp, M, Francois, C, Toumi, M, Brugha, TRelapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 184 2004 346351CrossRefGoogle ScholarPubMed
Awad, AG, Voruganti, LNThe burden of schizophrenia on caregivers: a review. Pharmacoeconomics 26 2008 149162CrossRefGoogle ScholarPubMed
Law, MR, Soumerai, SB, Ross-Degnan, D, Adams, ASA longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 69 2008 4753CrossRefGoogle Scholar
Kane, JMImproving patient outcomes in schizophrenia: achieving remission, preventing relapse, and measuring success. J Clin Psychiatry 74 2013 e18CrossRefGoogle ScholarPubMed
Weiden, PJ, Olfson, MCost of relapse in schizophrenia. Schizophr Bull 21 1995 419429CrossRefGoogle Scholar
Dolder, CR, Lacro, JP, Dunn, LB, Jeste, DVAntipsychotic medication adheren is there a difference between typical and atypical agents? Am J Psychiatry 159 2002 103108CrossRefGoogle Scholar
Diaz, E, Neuse, E, Sullivan, MC, Pearsall, HR, Woods, SWAdherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 65 2004 354360CrossRefGoogle ScholarPubMed
Nakonezny, PA, Byerly, MJElectronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs. second-generation antipsychotics. Schizophr Res 82 2006 107114CrossRefGoogle ScholarPubMed
Ucok, A, Polat, A, Cakir, S, Genc, AOne year outcome in first episode schizophrenia. Predictors of relapse. Eur Arch Psychiatry Clin Neurosci 256 2006 3743CrossRefGoogle Scholar
Alvarez-Jimenez, M, Priede, A, Hetrick, SE, Bendall, S, Killackey, E, Parker, AG , et al.Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res 139 2012 116128CrossRefGoogle ScholarPubMed
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO , et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 2005 12091223CrossRefGoogle ScholarPubMed
Kahn, RS, Fleischhacker, WW, Boter, H, Davidson, M, Vergouwe, Y, Keet, IP , et al.Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371 2008 10851097CrossRefGoogle ScholarPubMed
Acosta, FJ, Hernandez, JL, Pereira, J, Herrera, J, Rodriguez, CJMedication adherence in schizophrenia. World J Psychiatry 2 2012 7482CrossRefGoogle Scholar
Higashi, K, Medic, G, Littlewood, KJ, Diez, T, Granstrom, O, De Hert, MMedication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol 3 2013 200218CrossRefGoogle ScholarPubMed
Macaluso, M, McKnight, SOvercoming medication nonadherence in schizophrenia: Strategies that can reduce harm. Current Psychiatry 12 2013 1420Google Scholar
Acosta, FJ, Bosch, E, Sarmiento, G, Juanes, N, Caballero-Hidalgo, A, Mayans, TEvaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variables. Schizophr Res 107 2009 213217CrossRefGoogle ScholarPubMed
Hui, CL, Chen, EY, Kan, CS, Yip, KC, Law, CW, Chiu, CPDetection of non-adherent behaviour in early psychosis. Aust N Z J Psychiatry 40 2006 446451CrossRefGoogle ScholarPubMed
Velligan, DI, Lam, YW, Glahn, DC, Barrett, JA, Maples, NJ, Ereshefsky, L , et al.Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 32 2006 724742CrossRefGoogle ScholarPubMed
Kuipers, E, Yesufu-Udechuku, A, Taylor, C, Kendall, TManagement of psychosis and schizophrenia in adults: summary of updated NICE guidance. BMJ 348 2014 g1173CrossRefGoogle ScholarPubMed
Emsley, R, Chiliza, B, Asmal, L, de Fleuriot, MLong acting injectable antipsychotics in early psychosis. Haddad, PLambert, TLauriello, JAntipsychotic long-acting injections 2010 Oxford University Press Oxford145162CrossRefGoogle Scholar
Moore, TA, Buchanan, RW, Buckley, PF, Chiles, JA, Conley, RR, Crismon, ML , et al.The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 68 2007 17511762CrossRefGoogle ScholarPubMed
Malla, A, Tibbo, P, Chue, P, Levy, E, Manchanda, R, Teehan, M , et al.Long-acting injectable antipsychotics: recommendations for clinicians. Can J Psychiatry 58 2013 30S35SCrossRefGoogle ScholarPubMed
Llorca, PM, Abbar, M, Courtet, P, Guillaume, S, Lancrenon, S, Samalin, LGuidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry 13 2013 340CrossRefGoogle ScholarPubMed
West, JC, Marcus, SC, Wilk, J, Countis, LM, Regier, DA, Olfson, MUse of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull 34 2008 9951001CrossRefGoogle Scholar
Potkin, S, Bera, R, Zubek, D, Lau, GPatient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry 13 2013 261CrossRefGoogle Scholar
Heres, S, Hamann, J, Kissling, W, Leucht, SAttitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 67 2006 19481953CrossRefGoogle ScholarPubMed
Heres, S, Hamann, J, Mendel, R, Wickelmaier, F, Pajonk, FG, Leucht, S , et al.Identifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysis. Prog Neuropsychopharmacol Biol Psychiatry 32 2008 19871993CrossRefGoogle ScholarPubMed
Samalin, L, Charpeaud, T, Blanc, O, Heres, S, Llorca, PMClinicians’ attitudes toward the use of long-acting injectable antipsychotics. J Nerv Ment Dis 201 2013 553559CrossRefGoogle ScholarPubMed
Hamann, J, Kissling, W, Heres, SChecking the plausibility of psychiatrists arguments for not prescribing depot medication. Eur Neuropsychopharmacol 24 2014 15061510CrossRefGoogle Scholar
Weiden, PJ, Schooler, NR, Weedon, JC, Elmouchtari, A, Sunakawa, A, Goldfinger, SMA randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry 70 2009 13971406CrossRefGoogle ScholarPubMed
Kaplan, G, Casoy, J, Zummo, JImpact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence 7 2013 11711180CrossRefGoogle ScholarPubMed
Kim, B, Lee, SH, Choi, TK, Suh, S, Kim, YW, Lee, E , et al.Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry 32 2008 12311235CrossRefGoogle Scholar
Weiden, PJ, Schooler, NR, Weedon, JC, Elmouchtari, A, Sunakawa-McMillan, AMaintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study. J Clin Psychiatry 73 2012 12241233CrossRefGoogle ScholarPubMed
Malla, A, Chue, P, Jordan, G, Stip, E, Koczerginski, D, Milliken, H , et al.An Exploratory Open-Label Randomized Trial Comparing Risperidone Long Acting Injectable (RLAI) with Oral Antipsychotic Medication in the Treatment of Early Psychosis. Clin Schizophr Relat Psychoses 2013 126Google ScholarPubMed
Csernansky, JG, Mahmoud, R, Brenner, RA comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346 2002 1622CrossRefGoogle ScholarPubMed
Bartzokis, G, Lu, PH, Amar, CP, Raven, EP, Detore, NR, Altshuler, LL , et al.Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophr Res 132 2011 3541CrossRefGoogle ScholarPubMed
Bartzokis, G, Lu, PH, Raven, EP, Amar, CP, Detore, NR, Couvrette, AJ , et al.Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophr Res 140 2012 122128CrossRefGoogle ScholarPubMed
Adams, CE, Fenton, MK, Quraishi, S, David, ASSystematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 179 2001 290299CrossRefGoogle ScholarPubMed
Leucht, C, Heres, S, Kane, JM, Kissling, W, Davis, JM, Leucht, SOral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127 2011 8392CrossRefGoogle ScholarPubMed
Kishimoto, T, Nitta, M, Borenstein, M, Kane, JM, Correll, CULong-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 74 2013 957965CrossRefGoogle ScholarPubMed
Kirson, NY, Weiden, PJ, Yermakov, S, Huang, W, Samuelson, T, Offord, SJ , et al.Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 74 2013 568575CrossRefGoogle ScholarPubMed
Grimaldi-Bensouda, L, Rouillon, F, Astruc, B, Rossignol, M, Benichou, J, Falissard, B , et al.Does long-acting injectable risperidone make a difference to the reallife treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res 134 2012 187194CrossRefGoogle Scholar
Kane, JM, Kishimoto, T, Correll, CUAssessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol 66 2013 S37S41CrossRefGoogle Scholar
Manchanda, R, Chue, P, Malla, A, Tibbo, P, Roy, MA, Williams, R , et al.Long-acting injectable antipsychotics: evidence of effectiveness and use. Can J Psychiatry 58 2013 5S13SCrossRefGoogle ScholarPubMed
Tiihonen, J, Wahlbeck, K, Lonnqvist, J, Klaukka, T, Ioannidis, JP, Volavka, J , et al.Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333 2006 224CrossRefGoogle Scholar
Ventura, J, Subotnik, KL, Guzik, LH, Hellemann, GS, Gitlin, MJ, Wood, RC , et al.Remission and recovery during the first outpatient year of the early course of schizophrenia. Schizophr Res 132 2011 1823CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.